Who are Pivmecillinam hydrochloride tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Amoxil, Bicillin C-R, Bicillin C-R, anti-pseudomonal penicillin, Cefazolin and Metronidazole., Benzathine penicillin G.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pivmecillinam-hydrochloride-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Pivmecillinam hydrochloride tablets — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pivmecillinam hydrochloride tablets (Pivmecillinam hydrochloride tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic. Area: Infectious diseases.

phase 3 Beta-lactam antibiotic Penicillin-binding proteins (PBPs) Infectious diseases Small molecule Live · refreshed every 30 min

Target snapshot

Pivmecillinam hydrochloride tablets (Pivmecillinam hydrochloride tablets) — Benova (Tianjin) Innovative medicine Research Co., Ltd.. Pivmecillinam hydrochloride is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pivmecillinam hydrochloride tablets TARGET	Pivmecillinam hydrochloride tablets	Benova (Tianjin) Innovative medicine Research Co., Ltd.	phase 3	Beta-lactam antibiotic	Penicillin-binding proteins (PBPs)
Amoxil	amoxicillin	Generic (originally Beecham/GSK)	marketed	Aminopenicillin (Beta-lactam antibiotic)	5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C	1972-01-01
Bicillin C-R	Penicillin G Benzathine	Pfizer	marketed	Beta-lactam antibiotic	Cell-wall peptidoglycan biosynthesis	1952-01-01
Bicillin C-R	Penicillin G Benzathine	Pfizer	marketed	Beta-lactam antibiotic	Cell-wall peptidoglycan biosynthesis	1952-01-01
anti-pseudomonal penicillin	anti-pseudomonal penicillin	Vanderbilt University Medical Center	marketed	Beta-lactam antibiotic (anti-pseudomonal penicillin)	Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan
Cefazolin and Metronidazole.	Cefazolin and Metronidazole.	The University of Texas Health Science Center, Houston	marketed	Beta-lactam antibiotic and nitroimidazole antibiotic combination	Penicillin-binding proteins (cefazolin); anaerobic bacterial DNA (metronidazole)
Benzathine penicillin G	Benzathine penicillin G	International Maternal Pediatric Adolescent AIDS Clinical Trials Group	marketed	Beta-lactam antibiotic	Penicillin-binding proteins (PBPs)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-12-08 — Amoxil · 8778924 · Compound · US
2026-12-08 — Amoxil · 8357394 · Formulation · US
2027-05-07 — Amoxil · 8299052 · Method of Use · US

Sponsor landscape (Beta-lactam antibiotic class)

Pfizer · 2 drugs in this class
Bayer · 1 drug in this class
Belén Retamal-Valdes · 1 drug in this class
Benova (Tianjin) Innovative medicine Research Co., Ltd. · 1 drug in this class
Esraa Salah Mohamed Abdallah Eladl · 1 drug in this class
Incheon St.Mary's Hospital · 1 drug in this class
International Maternal Pediatric Adolescent AIDS Clinical Trials Group · 1 drug in this class
KEMRI-Wellcome Trust Collaborative Research Program · 1 drug in this class
National Taiwan University Hospital · 1 drug in this class
Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pivmecillinam hydrochloride tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/pivmecillinam-hydrochloride-tablets. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab